Pantoprazole Sodium is a proton pump inhibitor indicated for erosive esophagitis associated with GERD and Zollinger-Ellison syndrome. We supply it to US manufacturers of delayed-release tablets, delayed-release oral suspension and injection.
Data from PubChem (CID 67047490) and FDA’s substance registry
CAS number
164579-32-2
Molecular formula
C16H14F2N3NaO4S1.5H2O
Molecular weight
432.4g/mol
FDA UNII
IUPAC name
sodium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide sesquihydrate
InChIKey
RJRBTVMZZGMTQI-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Freely soluble in water, very slightly soluble in phosphate buffer at pH 7.4, and practically insoluble in n-hexane.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Supplied as the sesquihydrate. Injection-grade material has tighter limits than oral grade, so say which dosage form you make.
On the US market
- Reference product
- ProtonixNDA 020987
- Approved ANDAs
- 31 with a marketed product
- Approved forms and strengths
- Delayed-release tablet 20 mg, 40 mg
- Injection 40 mg per vial, 40 mg/100 mL, 40 mg/50 mL, 80 mg/100 mL
- Delayed-release granules for oral suspension 40 mg
- Powder for injection 40 mg per vial
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com